← Back to Search

Behavioural Intervention

Asymmetric Walking Protocols for ACL Reconstruction

N/A
Recruiting
Led By Kristin Morgan, PhD
Research Sponsored by University of Connecticut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, post-treatment (immediately following the completion of the second session)
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to find ways to restore healthy symmetric walking after ACLR surgery using asymmetric walking protocols & machine learning.

Who is the study for?
This trial is for individuals aged 18-30 who have undergone ACL reconstruction at the UConn Musculoskeletal Institute and are cleared to return to sport. They must show a significant difference in limb loading when walking, speak English, and not have other injuries or conditions that affect movement.
What is being tested?
The study tests two different asymmetric walking speeds (0.25 m/s and 0.50 m/s) first on people after ACL surgery to see which better restores balanced limb loading. It uses computational models and machine learning to analyze knee loading.
What are the potential side effects?
Since this trial involves physical activity protocols rather than drugs, side effects may include discomfort or fatigue due to the walking sessions but should not involve typical medication-related side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, post-treatment (immediately following the completion of the second session)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, post-treatment (immediately following the completion of the second session) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Knee Loading
Change in Loading Rate
Change in Peak Vertical Ground Reaction Force
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: 0.25 m/s asymmetric session firstActive Control1 Intervention
Participants will perform three 15-minute sessions of walking with a 0.25 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.25 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.
Group II: 0.50 m/s asymmetric walking session firstActive Control1 Intervention
Participants will perform three 15-minute sessions of walking with a 0.50 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.5 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.

Find a Location

Who is running the clinical trial?

University of ConnecticutLead Sponsor
192 Previous Clinical Trials
160,840 Total Patients Enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
502 Previous Clinical Trials
1,089,978 Total Patients Enrolled
1 Trials studying Anterior Cruciate Ligament Reconstruction
1,236 Patients Enrolled for Anterior Cruciate Ligament Reconstruction
Kristin Morgan, PhDPrincipal InvestigatorUniversity of Connecticut

Media Library

Asymmetric Walking Protocol (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05968729 — N/A
Anterior Cruciate Ligament Reconstruction Research Study Groups: 0.25 m/s asymmetric session first, 0.50 m/s asymmetric walking session first
Anterior Cruciate Ligament Reconstruction Clinical Trial 2023: Asymmetric Walking Protocol Highlights & Side Effects. Trial Name: NCT05968729 — N/A
Asymmetric Walking Protocol (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05968729 — N/A
~21 spots leftby Jul 2027